Funding profile · Radiology AI

Synapsica Healthcare

One disclosed round of $4.2 million, no SEC filings at all, and an Indian registry trail that stops in 2021. The capital picture here is small, single-jurisdiction and largely unaudited.

$4.2MSeries A announced June 22, 2021, the only disclosed round
Rs 31.3CrTotal raised since inception, company-reported (2022)
0SEC filings of any kind, including Form D
Rs 2.07CrFY2021 revenue, Indian subsidiary, as filed with the MCA

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2017 to 2019 Incorporation and early capital Not disclosed Not disclosed MCA
Winter 2020 Y Combinator batch Not disclosed Y Combinator YC directory
Jun 22, 2021 Series A $4.2M, about Rs 31.1 crore Led by IvyCap Ventures and Endiya Partners; Y Combinator and angel investors PTI and trade press
By 2022 Cumulative, company-reported Rs 31.3 crore Y Combinator, angels, IvyCap Ventures, Endiya Partners Company-stated
2022 to 2026 No further round announced None found None found Not found

What the filings show

Synapsica Technologies Private Limited · ROC Delhi · incorporated Jul 18, 2017

CIN
U74999DL2017PTC320790
Authorised capital
Rs 10 lakh
Paid-up capital
Rs 1.11 lakh
Last AGM
Sep 30, 2019
Last statements filed
Year ended Mar 31, 2019
Directors
Gandharv Goyal, Cherian, Meenakshi Singh, Mohd Kashif Rashid
Status
DPIIT recognised startup; marked compliant by the Registrar

Synapsica Healthcare Private Limited · ROC Delhi · incorporated Dec 23, 2019

CIN
U74999DL2019PTC359165
Authorised capital
Rs 1.4 crore
Paid-up capital
Rs 1.15 crore
Revenue
Rs 2.07 crore, FY2021
Last AGM
Nov 30, 2021
Last statements filed
Year ended Mar 31, 2021
Directors
Gandharv Goyal, Meenakshi Singh, Cherian
Parent
Synapsica Healthcare Inc
Charges
None registered

Synapsica Healthcare, Inc. · United States · no SEC filings

EDGAR company search
No matching companies, Sep 23, 2026
EDGAR full text search
Zero hits for Synapsica
Form D
None filed
Known US presence
2591 Dallas Parkway, Suite 300, Frisco, TX, named as 510(k) sponsor address

Reading the filings

  1. The US parent raised nothing under Regulation D.Synapsica Healthcare, Inc. is the named sponsor on FDA 510(k) K222174 and the recorded parent of the Indian operating company, yet EDGAR holds no filing under that or any similar name. Capital raised under Section 4(a)(2), or raised into the Indian entity, leaves no Form D. The absence is not evidence of no capital, but the usual filing trail is missing.
  2. The round is effectively the whole balance sheet.PTI put the June 2021 Series A at $4.2 million, about Rs 31.1 crore. A company-supplied profile the next year gave total funds raised since inception as Rs 31.3 crore. A gap of Rs 0.2 crore leaves almost no room for a separate seed, so the Series A is close to all of the outside capital.
  3. The round was priced well ahead of revenue.The Indian subsidiary reported Rs 2.07 crore of revenue for FY2021. The same company profile put annual recurring revenue at Rs 3.7 crore. Against that, $4.2 million is a multiple that only works if growth continues.
  4. The registry goes quiet after 2021.The last annual general meeting on record is Nov 30, 2021 and the last financial statements are for the year ended Mar 31, 2021, with about 44 employees recorded in April 2024. For a company that took institutional money in 2021, that gap is the loudest number on this page.
  5. Two entities, one regulatory asset.The operating company is an Indian subsidiary, while the only regulated product, RadioLens v1.0 with the SpindleX module, is cleared to the US parent. A buyer would be taking a K number on one side and a customer base on the other.
  6. Third party revenue estimates are not filings.A SaaS data aggregator lists an estimated $3.9 million of 2024 revenue and 26 employees, and on the same page shows funding as $0. The funding figure is demonstrably wrong, so the revenue figure deserves the same discount.

Commercial signals

Signal Detail Source type
Regulatory FDA 510(k) K222174, cleared Mar 28, 2023, for RadioLens v1.0 with the optional SpindleX stress X-ray module. Spindle for MRI spine is not cleared. No CE mark or CDSCO registration found. Public record
Distribution GenWorks Health, Wipro GE backed, for Radiolens across 300 plus tier 2 and 3 towns (2021). Spinal Kinetics in the US (2020). Partner-stated
Named customer Aarthi Scans and Labs, 40 centres and more than 900 MRI scans a day, deploying Spindle (May 2022). Partner-stated
Scale claims 500 to 600 locations, 15 countries, 1 million cases, later 2,000 radiologists and centres. Not independently audited. Company-stated
Clinical evidence One reader study, reported only inside the 510(k) summary. No PubMed paper, no registered trial. Not found
Going concern Y Combinator lists the company as Inactive. The last archived capture of synapsica.com is Jan 13, 2026 and the domain now serves a certificate for an unrelated host. No shutdown or sale was announced. Unresolved

What to watch

  • A newer set of financial statements on the Indian registry. The last filed year is FY2021.
  • Any assignment or transfer of 510(k) K222174, which would show where the regulatory asset went.
  • A first Form D, or any EDGAR appearance, from the US parent.
  • Whether IvyCap Ventures or Endiya Partners mark the position down or report an exit.

The Synapsica Healthcare story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Medium Biosciences: Shared investor: Independent Fund. A small San Francisco company that says it designs custom affinity reagents with AI and delivers them in weeks
  • InVision Medical Technology: Shared investor: Independent Fund. Two FDA-cleared models that read heart ultrasounds already being performed, built by the lab that published the underlying papers first
  • InnaMed: Also in Diagnostics. A Philadelphia startup that built a microneedle, cartridge-based blood testing platform called HomeLab, sold multi-year testing services to pharmaceutical companies, and
  • Orange Health Labs: Also in Diagnostics. An Indian diagnostics company that draws blood at home in under an hour and returns reports in six

Sources

  1. Public recordFDA 510(k) K222174, letter and summaryFDA · Mar 28, 2023
  2. Public recordSEC EDGAR company and full text search, no resultsSEC · Sep 23, 2026
  3. Public recordSynapsica Healthcare Private Limited, CIN U74999DL2019PTC359165MCA via The Company Check · Feb 13, 2026
  4. Public recordSynapsica Technologies Private Limited, CIN U74999DL2017PTC320790MCA via The Company Check · Feb 18, 2026
  5. IndependentSynapsica Healthcare raises $4.2mn from IvyCap and EndiyaThe Times of India, PTI · Jun 23, 2021
  6. IndependentFunding alert: Synapsica Healthcare raises $4.2MYourStory · Jun 23, 2021
  7. Independent#startupoftheday 113, Synapsica, total funds raised and ARRBioSpectrum India · 2022
  8. IndependentSynapsica Healthcare revenue and team estimatesGetLatka · accessed Sep 23, 2026
  9. CompanyY Combinator directory listing, status InactiveY Combinator · accessed Sep 23, 2026
  10. CompanySynapsica company page, offices and productsLinkedIn · accessed Sep 23, 2026

Compiled from SEC, FDA and Indian Ministry of Corporate Affairs public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; no such notice exists for this company, and companies that raise outside Regulation D file none. Healthcare Venture Capital Fund holds no position in Synapsica Healthcare. This page is not an offer to sell or a recommendation to buy any security.